Amgen 2015 Annual Report Download - page 53

Download and view the complete annual report

Please find page 53 of the 2015 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

45
The decrease in global NEUPOGEN® sales for 2015 was driven by a decline in unit demand due primarily to the impact of
short-acting competition in the United States.
The decrease in global NEUPOGEN® sales for 2014 was driven by the $155-million order from the U.S. government in
2013. Excluding the special order, U.S. and global sales declined 17% and 7%, respectively, which reflected declines in unit
demand in the United States, offset partially by the increased sales as a result of acquiring rights to filgrastim in certain international
areas effective January 1, 2014.
There is competition in the United States, which we expect will have a material adverse impact on future sales of
NEUPOGEN®. On September 3, 2015, Sandoz announced that they launched Zarxio™, a biosimilar version of NEUPOGEN®, in
the United States. On February 17, 2015, Apotex announced that the FDA accepted for filing its application, under the abbreviated
pathway, for its biosimilar version of NEUPOGEN®. For discussion of ongoing litigation, see Part IV—Note 18, Contingencies
and commitments, to the Consolidated Financial Statements.
See Part 1, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition and Part IV—Note
18, Contingencies and commitments, to the Consolidated Financial Statements.
Future NEUPOGEN® sales will also depend, in part, on the development of new protocols, tests and/or treatments for cancer
and/or new chemotherapy treatments or alternatives to chemotherapy that may have reduced and may continue to reduce the use
of chemotherapy in some patients.
Other products
Other product sales by geographic region were as follows (dollar amounts in millions):
Year ended
December 31,
Year ended
December 31,
Year ended
December 31,
2015 Change 2014 Change 2013
Vectibix® — U.S. $ 204 21% $ 168 33 % $ 126
Vectibix® — ROW 345 2% 337 28 % 263
Nplate® — U.S. 317 22% 260 8 % 241
Nplate® — ROW 208 —% 209 12 % 186
Kyprolis® — U.S. 467 53% 306 * 71
Kyprolis® — ROW 45 80% 25 * 2
Other — U.S. 84 * 3 N/A —
Other — ROW 207 —% 206 (16)% 246
Total other product sales $ 1,877 24% $ 1,514 33 % $ 1,135
Total U.S. — other products $ 1,072 45% $ 737 68 % $ 438
Total ROW — other products 805 4% 777 11 % 697
Total other product sales $ 1,877 24% $ 1,514 33 % $ 1,135
* Change in excess of 100%